<div id="readability-page-1"><p>Financial Consulate Inc. purchased a new stake in  Eli Lilly and Company (NYSE:LLY - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The firm purchased 1,229 shares of the company's stock, valued at approximately $938,000.</p><ul><li>MarketBeat Week in Review – 12/29 - 01/02</li></ul><p>Several other institutional investors also recently bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of  Eli Lilly and Company in the second quarter worth approximately $27,000.  Evolution Wealth Management Inc. purchased a new position in  Eli Lilly and Company in the 2nd quarter valued at $29,000.  Steph &amp; Co. boosted its stake in  Eli Lilly and Company by 290.0% during the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock worth $30,000 after purchasing an additional 29 shares during the last quarter.  Financial Gravity Companies Inc. purchased a new stake in shares of  Eli Lilly and Company during the second quarter worth $31,000.  Finally, Bare Financial Services Inc raised its position in shares of  Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company's stock valued at $31,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company Stock Up 0.5%</h2><p>Shares of NYSE LLY opened at $1,079.83 on Friday. The company has a market capitalization of $1.02 trillion, a P/E ratio of 52.83, a P/E/G ratio of 0.77 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a 50 day simple moving average of $1,013.16 and a 200-day simple moving average of $850.41. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. </p><ul><li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm's revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.  On average, equities research analysts predict that  Eli Lilly and Company will post 23.48 earnings per share for the current year. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio  is 29.35%. </p><h2>Analysts Set New Price Targets</h2><ul><li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li></ul><p>A number of research firms recently weighed in on LLY. Zacks Research upgraded shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday. Wolfe Research boosted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, December 3rd. JPMorgan Chase &amp; Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, November 18th. Wall Street Zen upgraded Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 1st. Finally, Scotiabank assumed coverage on Eli Lilly and Company in a research note on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $1,165.00 price objective on the stock. Five research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Buy&#34; and an average target price of $1,155.36.</p><p><b>Read Our Latest Research Report on LLY</b></p><h2>About Eli Lilly and Company</h2> (Free Report)<p>Eli Lilly and Company <span>NYSE: LLY<span></span></span> is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p><h2>Read More</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>Do not delete, read immediately</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>But this $2 Gold Stock Before May 20, 2026</li></ul><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Financial Consulate Inc. has invested $938,000 in Eli Lilly and Company (NYSE: LLY) by acquiring 1,229 shares during the third quarter. This investment comes amid a trend of institutional investors increasing their stakes in the company. Eli Lilly's stock opened at $1,079.83, with a market cap of $1.02 trillion and a P/E ratio of 52.83. The company reported strong quarterly earnings, exceeding estimates, and announced a dividend increase to $1.73 per share, reflecting a positive outlook from analysts who have upgraded their ratings and price targets for the stock.</p>

Financial Consulate Inc. Invests $938,000 in Eli Lilly and Company $LLY